LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX)

LPL Financial LLC purchased a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 13,321 shares of the company’s stock, valued at approximately $251,000.

Other hedge funds also recently bought and sold shares of the company. Caitlin John LLC raised its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Pacira BioSciences during the fourth quarter worth approximately $190,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analysts Set New Price Targets

PCRX has been the subject of several research analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays upped their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Finally, HC Wainwright upped their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and a consensus price target of $26.67.

Pacira BioSciences Stock Up 5.5 %

Shares of NASDAQ:PCRX opened at $27.14 on Tuesday. The stock has a market cap of $1.26 billion, a P/E ratio of -13.37 and a beta of 0.71. The firm has a fifty day moving average price of $24.52 and a 200 day moving average price of $21.61. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.